This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, D. L. Articles by Schwartz, M. W. Search for Related Content PubMed PubMed Citation Articles by Williams, D. L. Articles by Schwartz, M. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

Department of Psychology (D.L.W.), Florida State University, Tallahassee, Florida 32306-4301; and Diabetes and Obesity Center of Excellence (M.W.S.) and Department of Medicine (D.G.B., M.W.S.), Division of Metabolism, Endocrinology, and Nutrition, and Department of Biological Structure (D.G.B.), University of Washington, and Research and Development Service (D.G.B.), Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108

Address all correspondence and requests for reprints to: Diana L. Williams, B328, PDB, Department of Psychology, 1107 West Call Street, Florida State University, Tallahassee, Florida 32306-4301. E-mail: williams{at}psy.fsu.edu.

A physiological role in satiety is proposed for glucagon-like peptide-1 (GLP-1), secreted by the distal intestine in response to ingested nutrients. Here we report that in rats, ip injection of the GLP-1 receptor (GLP-1-R) antagonist exendin 9-39 (Ex9) elicited hyperphagia, but only at times of day when intake is otherwise low. Furthermore, ip administration of Ex9 attenuated satiety induced by either a voluntarily consumed sucrose meal (by 100%) or an intragastric glucose load (by 40%). To determine whether these effects involve blockade of GLP-1-R in brain or at a peripheral site, we injected Ex9 either centrally (into the third ventricle) or peripherally (ip) prior to GLP-1 injected either centrally or peripherally. Anorexia induced by peripheral GLP-1 was fully blocked by peripheral, but not central, pretreatment with Ex9, whereas the opposite was true for anorexic effect of central GLP-1. Thus, ip Ex9 appears to attenuate satiety via peripheral GLP-1-R blockade. Finally, anorexia induced by ip injection of exendin-4 (a GLP-1-R agonist) was due to both reduced meal size and increased duration between meals. We conclude that GLP-1 released from the intestine in response to ingested nutrients is a physiologically active satiety signal.

This article has been cited by other articles:

				D. L. Williams Minireview: Finding the Sweet Spot: Peripheral Versus Central Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis Endocrinology, July 1, 2009; 150(7): 2997 - 3001. [Abstract] [Full Text] [PDF]

				M. R. Hayes, L. Bradley, and H. J. Grill Endogenous Hindbrain Glucagon-Like Peptide-1 Receptor Activation Contributes to the Control of Food Intake by Mediating Gastric Satiation Signaling Endocrinology, June 1, 2009; 150(6): 2654 - 2659. [Abstract] [Full Text] [PDF]